Skip to main content
BAJAJHCARE · Health Care · 2026-08-07

Bajaj Healthcare Ltd

Stage 1 · wk 4In scan: Breakout WatchMARKET: BULL TOPPING · 2026-08-07
₹329.8
+0.18% today
₹1,110 Cr · Small cap
About this companyHealth Care· Pharmaceuticals
Expand ▾

Bajaj HealthCare Limited, a pharmaceutical company, develops, manufactures, markets, and sells active pharmaceutical ingredient, intermediates, and finished dosage forms and nutraceuticals for pharmaceutical, nutraceuticals, and food industries in India and internationally. The company offers active pharmaceutical ingredient in various therapeutic categories, including anti-diabetic, antibiotic, antiviral, antiplatelet, antifungal, antihelmintic, iron-chelating agent, anticonvulsant, growth stimulant, non-steroidal anti-inflammatory drugs, antihypertensive, anthelmintics, anti-asthmatic, antioxidant, urinary tract infection, anti-histamine, weight reducing, phlebotropic drug, antimalarial, vitamin c, disinfectant/ antiseptic, stimulant, lipotropic agents, nootropic, vasoprotective/antihemorrhagic, cardiovascular agents, food supplements, anti-anemic, amino acids, antiasthmatic / bronchodilator, nutritional supplement, and minerals. It provides intermediates, such as guanine, 3-methyl xanthine, bromoethyl theophylline, calcium phosphoryl choline chloride, 4-hydrazinobenzoic acid, ticagrelor acetonide, 4,7-dichloroquinolone, 5-[N-ethyl-N-(2-hydroxyethyl)amino]-2-aminopentane, 2-amino -4-hydroxyacetophenone, 8- chloro theophylline, 8 bromo-3-methyl xanthine, 3-methyl-7-(2-butyn-1-yl)-8-bromo xanthine, (S)-1-(2-chloroacetyl)pyrrolidine-2-carbonitrile, 3 – amino – 1 – adamantanol, N – boc -sitagliptin, sitagliptin base, hesperidine, (2,7-dichlori-9H-fluorene), (2-Chloro-1-(2,7- dichlori-9H-fluoren-4-yl)ethanone), (2-(dibutylamino)-1-(2, 7- dichlori-9H-fluoren-4-yl)ethanol), (2-Nitro-4-thiocyanoaniline), 4- (propylthio) benzene -1,2-diamine, methyl [(E)amino(methylsulfanyl)methylidene] carbamate, and (2-phenoxy methane sulphonamide). In addition, the company offers formulations in the form of tablets, capsules, sachets, and vials, as well as impurities. Bajaj HealthCare Limited was incorporated in 1993 and is based in Thane, India.

Visit company website →
P/E (TTM)
45.7
Forward —
ROE
+4.3%
Profit margin +2.6%
Dividend Yield
0.33%
P/B 1.8
vs 52W High
-35.0%
₹275 lo₹507.3 hi
35.0% below 52W high — far from high
Stock is basing below old highs. A volume-backed breakout to new highs would be the Stage 2 signal to watch.
Stage Maturity
Week 4
1w13w26w
Week 4 — early base, needs time
How long this stock has been basing. Longer bases can produce stronger breakouts — but don't anticipate, wait for the breakout.
vs 200 DMA
-8.3%
200 DMA: ₹359.8 · sloping down
Stock is testing its 200 DMA as part of the base. Reclaiming and holding above it is a key Stage 2 prerequisite.
Rel Volume
0.15x
vs 50-day avg
Volume in Stage 1 basing is typically quiet. A surge in volume on an upside breakout is the signal to watch.
Trend Health
MA20 rolling over · -2.0% vs MA50 +4.2%
Two-layer momentum read: the glyph shows whether the 20-day MA is rising (↑/↗), flat (→), or rolling over (↓). The ⇈ flag fires when the 20-day MA is pulling away from the 50-day MA — short-term momentum building on top of the longer trend. Best when both glyphs agree.
Sector
Health Care
↑ Building
Stage 2%
51.6%
20d Δ
+1.6pp
1M return
+3.1%
3M return
+11.6%
Sector Stage-2 % · last 20 days
Sector has 79 Stage 2 leaders. See Health Care Stage 2 →
Industry
Pharmaceuticals
→ Flat
Stage 2%
50.5%
20d Δ
+0.5pp
1M return
+1.9%
3M return
+11.7%
Industry Stage-2 % · last 20 days
Industry has 53 Stage 2 leaders. See Pharmaceuticals Stage 2 →
Price + Volume Chart
Loading price chart…
Stage Cycle Timeline2023-05-15 → 2026-08-07
S4 19w
S2 21w
S4 17w
S4 31w
2023-05-152026-08-07
S1S2S3S4Setup score (0–10, dashed line at 5)
S4 10w → S1 8w → S2 11w → S3 10w → S4 19w → S1 6w → S2 11w → S3 5w → S2 21w → S3 11w → S4 17w → S1 4w → S4 31w → S1 3w current
Total tracked: 168 weeks across 14 stage runs.
1M
-5.8%
3M
-2.0%
6M
-2.5%
YTD
-20.5%
1Y
-33.6%
Scan Membership
Breakout Watch
Latest: 2024-12-06
2 appearances in last 60 days. First seen: 2024-08-14.
Stocks that stay in the scan for 13+ weeks are in the highest observed-return cohort — they keep qualifying because the structure remains intact, not by luck. Persistence in the scan is itself a quality signal.
Recent Stage Timeline
2026-08-07S1
Wk 4 · Vol x
2026-08-06S1
Wk 4 · Vol x
2026-08-05S1
Wk 3 · Vol x
2026-08-04S1
Wk 3 · Vol x
2026-08-03S1
Wk 3 · Vol x
2026-07-31S1
Wk 3 · Vol x
2026-07-30S1
Wk 3 · Vol x
2026-07-29S1
Wk 2 · Vol x
2026-07-28S1
Wk 2 · Vol x
2026-07-27S1
Wk 2 · Vol x
2026-07-24S1
Wk 2 · Vol x
2026-07-23S1
Wk 2 · Vol x
Sector Peers — Stage 2All →
DIVISLAB
wk 12 · -3.6% from hi
8.5
LAURUSLABS
wk 16 · -0.3% from hi
8.4
PPLPHARMA
wk 4 · 0.0% from hi
8.2
LALPATHLAB
wk 9 · 0.0% from hi
7.9
SHILPAMED
wk 13 · 0.0% from hi
7.8
Moving averages & range
50 DMA
₹325.6
200 DMA
₹359.8
52W High
₹507.3
52W Low
₹275
5D Low
₹329.2
Resistance levels (recent highs)
20d High
₹386.6
60d High
₹386.6
120d High
₹386.6
250d High
₹507.3
Next resistance
+17.2%
to 20d High

All analytics based on EOD data. Data as of 2026-08-07. Past data patterns are not indicative of future results. This page is a data analytics tool only.